Who are Mycostatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abelcet, Amphotericin B Deoxycholate, Amphotericin B Liposome, Liposomal Amphotericin B, Amphotericin B Lipid emulsion, Conventional amphotericin B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nystatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Mycostatin — Competitive Intelligence Brief

Mycostatin (nystatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyene Antifungal [EPC]. Area: Infectious Disease.

marketed Polyene Antifungal [EPC] Ergosterol (fungal cell membrane) Infectious Disease Small molecule (natural product) Live · refreshed every 30 min

Target snapshot

Mycostatin (nystatin) — Generic (originally Squibb).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mycostatin TARGET	nystatin	Generic (originally Squibb)	marketed	Polyene Antifungal [EPC]	Ergosterol (fungal cell membrane)	1954-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	marketed	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Amphotericin B Deoxycholate	Amphotericin B Deoxycholate	Drugs for Neglected Diseases	marketed	Polyene antifungal	Ergosterol
Amphotericin B Liposome	Amphotericin B Liposome	Aurobindo Pharma Ltd	marketed	Lipid-based Polyene Antifungal [EPC]
Liposomal Amphotericin B	Liposomal Amphotericin B	Taiwan Liposome Company	marketed	Polyene antifungal	Ergosterol
Amphotericin B Lipid emulsion	Amphotericin B Lipid emulsion	Bharat Serums and Vaccines Limited	phase 3	Polyene antifungal	Ergosterol
Conventional amphotericin B	Conventional amphotericin B	Pfizer	phase 3	Polyene antifungal	Ergosterol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyene Antifungal [EPC] class)

Generic (originally Squibb) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycostatin — Competitive Intelligence Brief. https://druglandscape.com/ci/nystatin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab